QLGN - Qualigen Market Capitalization

Qualigen Therapeutics generates revenue from the sale of rapid blood tests and plans to expand profits through new cancer and antiviral drugs. This chart illustrates that the asset's market value is 0.01, highlighting the potential of strategic alliances with scientists to create innovative molecules and attract buyers. Meanwhile, partner plants are configuring high-precision equipment for the current stages of clinical trials.

QLGN Qualigen Therapeutics, Inc.: Market Capitalization in the range 07/04/2022 - 11/19/2025

Comprehensive metric breakdowns and analytics for Qualigen Corp (QLGN)

- market price and analyst price targets:

Price Chart Qualigen Therapeutics, Inc.|QLGN - Price Target Chart

- market capitalization statistics:

Market Capitalization Qualigen Corp|QLGN - Full Takeover Company Value

- issuer book value statistics:

Net Assets per Single Share Qualigen Therapeutics|QLGN - Accounting Capitalization|Market Value to Book Value Ratio qualigeninc.com|QLGN - Total Asset Value of Company

- debt and liquidity details:

Total Debt to Capital Qualigen Therapeutics|QLGN - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Qualigen Therapeutics|QLGN - Company Aggregate Debts|Debt to Book Capitalization Ratio Qualigen Corp|QLGN - Company Long-Term Loans and Borrowings|Company Short-Term Debt Qualigen Therapeutics|Quick Ratio qualigeninc.com

- business earnings and investment ratios data:

QLGN - Net Profit|Future Profit Qualigen Therapeutics|QLGN - Company Value to Net Income|Projected Price to Earnings Qualigen|QLGN - Price/Earnings to Growth Ratio|EV/EBITDA Multiple Qualigen Corp|QLGN - Operating income before deduction of amortization|Earnings per share for the last twelve months Qualigen Therapeutics|QLGN - Earnings per share for the trailing year|Year-over-year net earnings per share growth for the last 12 months qualigeninc.com|QLGN - Earnings growth in current year|Net earnings per share growth forecast for next year Qualigen Therapeutics

Fundamental company analysis:QLGN (Qualigen Therapeutics, Inc.)

The development of innovative methods to combat oncology and viruses determines the market value of Qualigen Therapeutics (QLGN). By analyzing the issuer's capitalization level, an investor sees the aggregate value of all the company's shares. This indicator is calculated as the product of the current share price and the total number of issued securities. The metric's dynamics reflect the market's confidence in the success of the biotechnological platforms. The stability of this value confirms the business's resilience to macroeconomic shocks.

Key competitors